Neumora Therapeutics Study of Depression Treatment Misses Primary, Secondary Endpoints

Dow Jones

Jan 02

By Denny Jacob

Neumora Therapeutics said a study of major depressive disorder treatment navacaprant didn't demonstrate a statistically significant improvement.

Trading was halted at 6:55 a.m. ET ahead of the disclosure. The stock closed Tuesday at $10.60.

The clinical-stage biopharmaceutical company said the Phase 3 study didn't demonstrate a statistically significant improvement on the primary endpoint of change from baseline in a scale that measures depression at Week 6 or the key secondary endpoint of change from baseline in a separate scale.

"The outcome of KOASTAL-1 is not what we expected, but there are encouraging trends in the data that we are analyzing," said Chief Executive Henry Gosebruch.

Neumora said navacaprant was shown to be safe and generally well-tolerated with no serious adverse events reported.

Write to Denny Jacob at denny.jacob@wsj.com

(END) Dow Jones Newswires

January 02, 2025 07:17 ET (12:17 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2500940041"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2500940041\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2500940041?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-02 20:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2500940041","market":"sg","top_or_hot":-1,"title":"Neumora Therapeutics Study of Depression Treatment Misses Primary, Secondary Endpoints","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Denny Jacob \n</p>\n<pre>\n \n</pre>\n<p>\n  Neumora <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> said a study of major depressive disorder treatment navacaprant didn't demonstrate a statistically significant improvement. \n</p>\n<p>\n  Trading was halted at 6:55 a.m. ET ahead of the disclosure. The stock closed Tuesday at $10.60. \n</p>\n<p>\n  The clinical-stage biopharmaceutical company said the Phase 3 study didn't demonstrate a statistically significant improvement on the primary endpoint of change from baseline in a scale that measures depression at Week 6 or the key secondary endpoint of change from baseline in a separate scale. \n</p>\n<p>\n  \"The outcome of KOASTAL-1 is not what we expected, but there are encouraging trends in the data that we are analyzing,\" said Chief Executive Henry Gosebruch. \n</p>\n<p>\n  Neumora said navacaprant was shown to be safe and generally well-tolerated with no serious adverse events reported. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Denny Jacob at denny.jacob@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 02, 2025 07:17 ET (12:17 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Neumora Therapeutics Study of Depression Treatment Misses Primary, Secondary Endpoints</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNeumora Therapeutics Study of Depression Treatment Misses Primary, Secondary Endpoints\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-01-02 20:17</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Denny Jacob \n</p>\n<pre>\n \n</pre>\n<p>\n  Neumora <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> said a study of major depressive disorder treatment navacaprant didn't demonstrate a statistically significant improvement. \n</p>\n<p>\n  Trading was halted at 6:55 a.m. ET ahead of the disclosure. The stock closed Tuesday at $10.60. \n</p>\n<p>\n  The clinical-stage biopharmaceutical company said the Phase 3 study didn't demonstrate a statistically significant improvement on the primary endpoint of change from baseline in a scale that measures depression at Week 6 or the key secondary endpoint of change from baseline in a separate scale. \n</p>\n<p>\n  \"The outcome of KOASTAL-1 is not what we expected, but there are encouraging trends in the data that we are analyzing,\" said Chief Executive Henry Gosebruch. \n</p>\n<p>\n  Neumora said navacaprant was shown to be safe and generally well-tolerated with no serious adverse events reported. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Denny Jacob at denny.jacob@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 02, 2025 07:17 ET (12:17 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2500940041","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2500940041","pubTimestamp":1735820220,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Neumora Therapeutics said a study of major depressive disorder treatment navacaprant didn't demonstrate a statistically significant improvement.Trading was halted at 6:55 a.m. ET ahead of the disclosure. The stock closed Tuesday at $10.60.The clinical-stage biopharmaceutical company said the Phase 3 study didn't demonstrate a statistically significant improvement on the primary endpoint of change from baseline in a scale that measures depression at Week 6 or the key secondary endpoint of change from baseline in a separate scale.\"The outcome of KOASTAL-1 is not what we expected, but there are encouraging trends in the data that we are analyzing,\" said Chief Executive Henry Gosebruch.Neumora said navacaprant was shown to be safe and generally well-tolerated with no serious adverse events reported.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","LENZ":"Therapeutics","NMRA":"Neumora Therapeutics, Inc.","BK4139":"生物科技"},"translate_title":"Neumora Therapeutics抑郁症治疗研究未达到主要和次要终点","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1,"NMRA":1},"content_text":"By Denny Jacob \n\n\n \n\n\n  Neumora Therapeutics said a study of major depressive disorder treatment navacaprant didn't demonstrate a statistically significant improvement. \n\n\n  Trading was halted at 6:55 a.m. ET ahead of the disclosure. The stock closed Tuesday at $10.60. \n\n\n  The clinical-stage biopharmaceutical company said the Phase 3 study didn't demonstrate a statistically significant improvement on the primary endpoint of change from baseline in a scale that measures depression at Week 6 or the key secondary endpoint of change from baseline in a separate scale. \n\n\n  \"The outcome of KOASTAL-1 is not what we expected, but there are encouraging trends in the data that we are analyzing,\" said Chief Executive Henry Gosebruch. \n\n\n  Neumora said navacaprant was shown to be safe and generally well-tolerated with no serious adverse events reported. \n\n\n \n\n\n  Write to Denny Jacob at denny.jacob@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 02, 2025 07:17 ET (12:17 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}